Eikonizo is developing brain-penetrant, small molecule, selective histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy (CIPN) and Alzheimer’s disease.
Eikonizo is also developing peripherally-restricted, small molecule, selective HDAC6 inhibitors for ADPKD and cardiac indications.